Doxifluridine

Doxifluridine is an antineoplastic agent used in the treatment of cancer. It is a prodrug of 5-fluorouracil (5-FU), a pyrimidine analog that interferes with DNA synthesis and RNA synthesis, leading to cell death and thus, has a cytotoxic effect on rapidly dividing cancer cells. Doxifluridine is specifically designed to be activated only within the tumor tissue, aiming to increase the concentration of the active drug in the tumor while minimizing the exposure of healthy tissues to the cytotoxic effects of 5-FU.

Mechanism of Action

Doxifluridine is metabolized in the liver to 5-FU, which then inhibits thymidylate synthase, an enzyme crucial for DNA synthesis. This inhibition results in the depletion of thymidine triphosphate (dTTP), which is necessary for DNA replication and repair. Consequently, the drug induces cell cycle arrest and apoptosis in cancer cells. Additionally, 5-FU is incorporated into RNA, disrupting RNA processing and function.

Clinical Uses

Doxifluridine has been studied and used in the treatment of various types of cancers, including breast cancer, gastric cancer, and colorectal cancer. Its efficacy and safety profile make it a valuable option in the chemotherapeutic regimen for these malignancies, often in combination with other anticancer agents to enhance therapeutic outcomes.

Pharmacokinetics

After oral administration, doxifluridine is rapidly absorbed from the gastrointestinal tract. Its bioactivation to 5-FU primarily occurs in the liver, but also in tumor tissues, which allows for a more targeted anticancer effect. The pharmacokinetics of doxifluridine and its active metabolite, 5-FU, are crucial for its antitumor activity and toxicity profile.

Adverse Effects

The adverse effects of doxifluridine are similar to those of 5-FU and include myelosuppression, characterized by decreased white blood cell, red blood cell, and platelet counts, which increases the risk of infection, anemia, and bleeding. Other common side effects include nausea, vomiting, diarrhea, and mucositis. Due to its mechanism of action, doxifluridine can also cause hand-foot syndrome, a condition characterized by redness, swelling, and pain on the palms of the hands and the soles of the feet.

Contraindications

Doxifluridine is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should also be used with caution in patients with severe renal or hepatic impairment, as these conditions can affect the drug's metabolism and excretion, potentially leading to increased toxicity.

Drug Interactions

Doxifluridine can interact with other medications that affect DNA and RNA synthesis, such as other chemotherapeutic agents, which may enhance both its therapeutic effects and toxicity. It is important to closely monitor patients for adverse effects when doxifluridine is used in combination with other drugs.

Conclusion

Doxifluridine represents an important option in the treatment of certain cancers, offering the potential for targeted therapy with its prodrug design. However, its use requires careful consideration of its pharmacokinetics, potential adverse effects, and interactions with other medications to optimize patient outcomes.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian